Document is current
Any future updates will be listed below
-
Authors
Wing, Casey E. https://orcid.org/0000-0002-6437-0129
Fung, Ho Yee Joyce https://orcid.org/0000-0002-0502-1957
Kwanten, Bert https://orcid.org/0000-0003-4459-5299
Cagatay, Tolga https://orcid.org/0000-0003-0256-7636
Niesman, Ashley B. https://orcid.org/0009-0008-0118-7483
Jacquemyn, Maarten https://orcid.org/0000-0003-2626-4189
Gharghabi, Mehdi https://orcid.org/0000-0001-8030-3121
Permentier, Brecht https://orcid.org/0009-0000-5353-0919
Shakya, Binita
Nandi, Rhituparna https://orcid.org/0000-0002-7907-7195
Ready, Joseph M. https://orcid.org/0000-0003-1305-9581
Kashyap, Trinayan
Shacham, Sharon
Landesman, Yosef
Lapalombella, Rosa https://orcid.org/0000-0001-6916-9400
Daelemans, Dirk https://orcid.org/0000-0001-7092-1153
Chook, Yuh Min https://orcid.org/0000-0002-4974-0726
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM144137)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM131963)
Welch Foundation (I-1532)
Cancer Prevention and Research Institute of Texas (RP150053)
Cancer Prevention and Research Institute of Texas (RP170170)
Cancer Prevention and Research Institute of Texas (RP210041)
U.S. Department of State
Fonds Wetenschappelijk Onderzoek (G0E6517N)
- License Information
-
More Information
Article History
Received: 22 May 2025
Accepted: 25 September 2025
First Online: 21 November 2025
Competing interests
: Y.M.C. was a consultant to and holds equity options in Karyopharm Therapeutics. Y.M.C. is also a consultant to Telo Therapeutics. B.K., M.J., B.P. and D.D. are employees of KU Leuven, which has a license agreement on KPT-SINE–XPO1 inhibitors. Y.L. was an employee of Karyopharm Therapeutics and still retains ownership of company shares. S.S. is a former employee of Karyopharm Therapeutics, holds patents (8999996, 9079865, 9714226, PCT/US12/048319 and I574957) on hydrazide-containing nuclear transport modulators and uses and holds pending patents (PCT/US12/048319, 499/2012, PI20102724 and 2012000928) on hydrazide-containing nuclear transport modulators and uses. The other authors declare no competing interests.
